Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.
about
Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practiceComparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trialProtease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected childrenBoosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patientsActual medication pill burden and dosing frequency in HIV-infected patients with undetectable viral loads.A pathophysiological approach to antiretroviral therapy.Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children.Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections."One pill, once daily": what clinicians need to know about Atriplatrade mark.Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsulesNo clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.Better adherence with once-daily antiretroviral regimens: a meta-analysisSteady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adultsLower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.Ritonavir-boosted protease inhibitors in HIV therapy.Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities.Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patientsLopinavir inhibits insulin signaling by promoting protein tyrosine phosphatase 1B expression.The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients.Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.Once daily dosing improves adherence to antiretroviral therapy.Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women.Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy
P2860
Q33681426-5212F9AD-7E2E-488F-B112-165189E6A1B1Q33708071-2692DE18-D941-45B5-9753-443BBC38CB48Q34631149-3BDEF4E8-6DCA-4446-A9EE-1F79C671BFACQ34776414-B60B8114-2837-4FD1-B81E-F342BA2ECB27Q35191590-2B613D4F-A803-48F1-8F0E-7E5CC8E0812EQ35539510-99B0ABB4-C4DA-4C8A-A503-9114CA36A2BBQ35557224-0C49FD18-9A58-46C8-99B5-3EF3DD651FC2Q35826931-7569D7CF-08FB-415F-891B-045076A9FB53Q35878022-FD6E4DD4-EAC8-4913-9DA6-DA497BF11CBBQ35917460-670B5F7C-3B75-47CD-AE5A-6EC795E9BD80Q36222013-F7A8F6E1-1D1A-427E-B00D-3CB8E83B0412Q36282719-5F7C4C9B-1ECF-4C9D-833E-BFD8C3AA6D8DQ36723780-035136FD-4A9A-41D1-8DD2-BE1628FB7AE0Q36823570-BBD5836E-F290-406F-AF02-E997F4310EBBQ36870827-E20B0311-A0D5-4025-8F1C-E06527E4128DQ36903907-D9422DB4-537E-4413-9153-A5DB11C3E97DQ36926668-08538ABA-5813-42BE-B413-20B4810FAF28Q37146865-A9DE13DC-0F17-4E73-B622-9944A1046079Q37174248-6A2E569B-E755-44AF-8122-BF4698BD58A0Q37255897-22BF7624-0F90-470D-B2F2-28608D066599Q37598597-92D8DC9B-7B55-4779-9B0D-87E0DF57D9A7Q37696578-C3A570B5-7B44-4715-9750-2ACFF8AB9AD9Q37866319-7A3A06F4-DBEC-4419-ACFF-2198389223EBQ38069146-840ABAB3-C87D-4B9F-8260-03032CE8055AQ38392893-AB97F68B-B35B-4942-8A5C-5748968DAC07Q39064765-24D7B686-8758-4B44-8314-69B19EFB028AQ40189483-89E53D6E-FE2C-4D2B-8603-C9A9AF96789FQ41910769-BC7C5607-BC83-4236-B42D-EDFA028B7ECDQ42289070-965DA449-1E09-42F8-9E7F-BBA1E6F9FCAEQ42652393-AF5E21DF-22AE-4E3D-9ADE-F758D0C97D17Q43244207-322B0DEB-2C6E-460F-BFAA-ED9C4706F28FQ43260037-6FCC6CA4-5D74-4B95-B11C-12AAD476FC2DQ45226018-23294DEE-5E1C-424D-BF04-F77B764F3233Q45353663-7A87B96A-BEEA-41FE-8790-9523ACF4D06DQ46065788-0EF6F0F3-CEAB-4EB9-92DB-AE79DBEC520CQ46173618-EC62619D-8961-4DB5-A2D4-A3E8C10E3CA4Q46794117-A9727D78-BA38-4754-92A7-AA1CECF2C13BQ46935140-B1A0B79F-4858-4AD7-A3F2-3FA7A9FD57ADQ57259708-1C74BDC3-A2A7-45BE-B9EE-FA1110941E5C
P2860
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Once-daily versus twice-daily ...... eek randomized clinical trial.
@en
Once-daily versus twice-daily ...... eek randomized clinical trial.
@nl
type
label
Once-daily versus twice-daily ...... eek randomized clinical trial.
@en
Once-daily versus twice-daily ...... eek randomized clinical trial.
@nl
prefLabel
Once-daily versus twice-daily ...... eek randomized clinical trial.
@en
Once-daily versus twice-daily ...... eek randomized clinical trial.
@nl
P2093
P356
P1476
Once-daily versus twice-daily ...... eek randomized clinical trial.
@en
P2093
Barry Bernstein
Bienvenido G Yangco
David A Wheeler
Donna Mildvan
Eugene Sun
Felix F Carpio
Harold A Kessler
Harold W Horowitz
Judith Feinberg
Mallory D Witt
P304
P356
10.1086/380799
P407
P577
2004-01-07T00:00:00Z